Open access · US-GOV via ClinicalTrials.gov Clinical trial

Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3)

Authors not listed

Lymphoma Study Association · 2003

Dysbiosis Human Randomized controlled trial

Abstract

This study is a multicentric trial evaluating the efficacy of R-ACVBP in patients aged 18 to 59 years with high risk diffuse large B-cell lymphoma

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-11-01 MST

Cite this

APA

Anonymous. (2003). Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3). <em>Lymphoma Study Association</em>. https://clinicaltrials.gov/study/NCT00144807

Vancouver

Anonymous. Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3). Lymphoma Study Association. 2003.

BibTeX

@misc{anon2003Studyo, title = {Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3)}, author = {Anonymous}, journal = {Lymphoma Study Association}, year = {2003}, }